Início › Câncer de Pulmão de Não Pequenas Células › Indiana › Indianapolis
Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Indianapolis, IN
32 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Indianapolis e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RecrutandoFase 3
- Saint Catherine Hospital, Indianapolis
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RecrutandoFase 3
- Saint Catherine Hospital, Indianapolis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecrutandoFase 1
- IU Simon Cancer Center, Indianapolis
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RecrutandoFase 3
- Franciscan Health ( Site 0219), Indianapolis
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecrutandoFase 1
- Exelixis Clinical Site #4, Indianapolis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecrutandoFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- IU Health West Hospital, Avon · a 13 mi de distância
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RecrutandoFase 1
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecrutandoFase 3
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecrutandoFase 3
- Franciscan Health, Indianapolis
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RecrutandoFase 2/3
- Indiana University Health University Hospital, Indianapolis
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RecrutandoFase 1/2
- Indiana University (IU) Health - Multi-D Oncology Clinic, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecrutandoFase 1/2
- Community Health Network, Indianapolis
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecrutandoFase 3
- Clinical Study Site, Indianapolis
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
RecrutandoFase 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecrutandoFase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
- Community Cancer Center North, Indianapolis
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
RecrutandoFase 1
- Community Health Network, Indianapolis
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RecrutandoFase 1
- Community Health Network, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecrutandoFase 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- e mais 1
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecrutandoFase 3
- Franciscan Health Indianapolis, Indianapolis
A Study of LY4175408 in Participants With Advanced Cancer
RecrutandoFase 1
- Community Health Network, Indianapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecrutandoFase 1
- Community Health Network, Inc. /ID# 243011, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2/3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
RecrutandoFase 2
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RecrutandoFase 2
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
A Study of VET3-TGI in Patients With Solid Tumors
RecrutandoFase 1
- Community Health Network, Indianapolis
Repositioning Immunotherapy in VetArans With Lung Cancer
RecrutandoFase 2
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RecrutandoFase 1/2
- Research Site, Indianapolis
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Recrutando
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
GEMINI-NSCLC: NSCLC Biomarker Study
RecrutandoEstudo observacional
- Community Health Network, Indianapolis
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
Recrutando
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecrutandoFase 1/2
- Community Health Network, Inc., Indianapolis
Ensaios de Câncer de Pulmão de Não Pequenas Células em outras cidades
- Houston, TX145 estudos
- New York City, NY121 estudos
- Arlington, VA104 estudos
- Nashville, TN97 estudos
- Boston, MA90 estudos
- Los Angeles, CA87 estudos
- St. Louis, MO73 estudos
- Chicago, IL61 estudos
- Baltimore, MD60 estudos
- San Antonio, TX59 estudos
- Columbus, OH57 estudos
- Washington, DC55 estudos
Outros estudos em Indianapolis
- Câncer (todos os tipos)24 estudos
- Insuficiência Cardíaca23 estudos
- Obesidade20 estudos
- Câncer de Mama20 estudos
- Câncer Metastático19 estudos
- Câncer Colorretal18 estudos
- Câncer de Ovário17 estudos
- Doença Cardiovascular17 estudos
- Câncer de Pulmão16 estudos
- Diabetes Tipo 114 estudos
- Câncer Endometrial14 estudos
- Doença de Alzheimer14 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.